TICKERNERD
Menu
FATEFATEHealthcare · Biotechnology

FATE Stock Forecast: Fate Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.57
+1.98% on the day

The 12 Wall Street analysts covering Fate Therapeutics, Inc. hold a median 12-month price target of $6 — +133.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$299.6M
Ticker Nerd rank
95 / 100
Median analyst target
$6.00
Analysts covering
12
Total return, dividends reinvested
1W
−8.2%
1M
−14.0%
YTD
+162.2%
1Y
+140.2%
From 52W high
−17.4%
From 52W low
+170.5%
$0.95
$3.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FATE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Momentum
84
Accruals
81
Revisions
74
Issuance
72
Quality
66
Size
62
Value
59
Volatility
20

Growth (94): Sales and profits are climbing, and climbing faster than before.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FATE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FATE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26FATEHigh $8.00Median $6.00Low $2.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
6 Buy6 Hold0 Sell
Low $2.20Median $6.00High $8.00

The green dot is the last close — the median target sits +133.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026HC Wainwright & Co.ReiteratesBuy$7.00
4 May 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.UpgradeBuy—
27 Oct 2025NeedhamReiteratesHold—
27 Oct 2025WedbushUpgradeOutperform—
13 Aug 2025Wells FargoMaintainsEqual-Weight—
12 June 2025NeedhamReiteratesHold—
14 May 2025BairdMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025NeedhamReiteratesHold—
6 Mar 2025NeedhamReiteratesHold—
6 Mar 2025StifelMaintainsHold—
6 Mar 2025WedbushReiteratesNeutral—
6 Mar 2025Wells FargoMaintainsEqual-Weight—
19 Nov 2024NeedhamReiteratesHold—
13 Nov 2024NeedhamReiteratesHold—
22 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
14 Aug 2024NeedhamReiteratesHold—
17 June 2024Piper SandlerUpgradeOverweight—
16 May 2024HC Wainwright & Co.MaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FATE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

FATE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Fate Therapeutics, Inc. (FATE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 86% of US stocks

Price / sales
46.1×

Cheaper than 6% of US stocks

Price / book
2.0×

Cheaper than 48% of US stocks

EV / EBITDA
−1.9×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
9.2%

Higher than 50% of US stocks

Earnings growth (YoY)
−20.3%

Higher than 20% of US stocks

Gross margin
—
Operating margin
−1495.4%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−60.8%

Higher than 19% of US stocks

Return on assets
−26.2%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FATE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FATEFate Therapeutics, Inc.$299.6M
95
AVXLAnavex Life Sciences Corp.$298.4M
21
IFRXInflaRx NV$300.5M
9
IRDOpus Genetics, Inc.$293.8M
50
NMRANeumora Therapeutics, Inc.$291.3M
38
TRDAEntrada Therapeutics, Inc.$289.6M
51
VNDAVanda Pharmaceuticals, Inc.$308.5M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FATE news & analysis

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewsWire · 14 Aug 2026positive

Fate Therapeutics has initiated the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, and multiple patients are in the process of screening at several activated sites.

Why it matters — For a FATE watcher, advancing FT819 into a potentially registrational trial marks a significant clinical milestone for the company's lupus nephritis program.

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

Fate Therapeutics reported a Q2 loss of $0.25 per share, narrower than both the Zacks Consensus Estimate of a $0.28 loss and the $0.29 loss from a year ago. Revenue also topped estimates.

Why it matters — The smaller-than-expected quarterly loss and revenue beat suggest the company's financial performance is improving relative to analyst expectations and the prior year.

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

GlobeNewsWire · 13 Aug 2026positive

Fate Therapeutics reported its second quarter 2026 financial results and business updates. The company also announced that the first lupus nephritis patient has been dosed in RECLAIM-LN, a Phase 2 potentially registrational trial of FT819, its iPSC-derived, off-the-shelf CAR T-cell therapy, with the patient treated as an outpatient and discharged the same day.

Why it matters — A FATE watcher would care because the dosing of the first patient in a potentially registrational Phase 2 trial represents a key step toward advancing FT819 in lupus nephritis.

FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says

Fox Business · 5 Aug 2026neutral

Sen. Cynthia Lummis discussed the expected CLARITY Act vote, the budget agenda ahead of recess, Congress' August checklist, and the Democratic Party's direction after Tuesday's primaries on "Mornings with Maria." The report does not mention Fate Therapeutics or its business.

Why it matters — The item contains no information relating to Fate Therapeutics, so a FATE watcher would find it unrelated to the company's operations or outlook.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Aug 2026neutral

On August 1, 2026, Fate Therapeutics granted inducement equity awards to three newly-hired non-executive employees: non-qualified stock options to purchase 37,300 shares at an exercise price of $2.45 per share and RSUs covering 45,300 shares. The awards were approved by the Compensation Committee under the company's Amended and Restated Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4), with both options and RSUs vesting over four years.

Why it matters — This gives FATE watchers routine detail on share-based compensation issued as hiring inducements to new employees, which can modestly affect the company's outstanding share count over time.

FAQ

Frequently asked questions about FATE stock

What is the FATE stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Fate Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $2.2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FATE stock a buy right now?

Of the 12 analysts covering Fate Therapeutics, Inc., 6 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fate Therapeutics, Inc. 95 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FATE?

As at 15 Aug 2026, Fate Therapeutics, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will FATE stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +133.5% from the last close, and Ticker Nerd's factor model ranks Fate Therapeutics, Inc. 95 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FATE stock forecast for 2030?

No analyst covering Fate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FATE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.2 to $8 over the next 12 months.

How has FATE stock performed over the past year?

Fate Therapeutics, Inc. returned +140.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fate Therapeutics, Inc. do?

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using induced pluripotent stem cell (iPSC) technology to treat cancer and autoimmune diseases.

What is the latest news on FATE?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis". Fate Therapeutics has initiated the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, and multiple patients are in the process of screening at several activated sites.

Company

About Fate Therapeutics, Inc.

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using induced pluripotent stem cell (iPSC) technology to treat cancer and autoimmune diseases. The company's pipeline includes FT819, an off-the-shelf CAR T-cell candidate for systemic lupus erythematosus and other autoimmune conditions, which has demonstrated rapid B-cell depletion and durable clinical responses in Phase 1 studies with reduced or eliminated conditioning chemotherapy requirements. Additional programs include FT825 and FT836 for various solid tumors and hematologic cancers, and FT522 for B-cell lymphoma. Fate Therapeutics' approach focuses on multiplexed-engineered cell products designed to overcome manufacturing and development limitations inherent to traditional cell therapies. The company emphasizes the potential for same-day discharge and outpatient administration of its therapies, aiming to make cell therapy delivery more routine and accessible while addressing significant unmet medical needs in oncology and immunology.

CEO Dr. Bahram Valamehr M.B.A., Ph.D. · 161 employees · United States · https://www.fatetherapeutics.com